V
Vero Biotech
An emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients…
About Vero Biotech
Vero Biotech is a healthcare startup that has developed a revolutionary nitric oxide delivery system called GENOSYL®. This system is designed to meet the needs of patients and healthcare providers in critical care settings where inhaled nitric oxide is part of the treatment plan. The company operates in the medical technology market, specifically in the segment of respiratory care.
Read full description
The GENOSYL® system is unique because it is the first tankless inhaled nitric oxide delivery system. This means it does not require heavy, pressurized gas cylinders, which are typically used for nitric oxide administration. Instead, it uses a compact, lightweight, and disposable cassette that generates nitric oxide on demand. This makes the system safer, more convenient, and easier to use than traditional methods. It also eliminates the need for special storage or disposal requirements, making it more cost-effective for healthcare providers.
Vero Biotech's business model is based on selling these disposable cassettes and the GENOSYL® delivery system to hospitals and other healthcare facilities. The company makes money by selling these products directly to these institutions or through medical supply distributors.
In summary, Vero Biotech is a medical technology company that has developed a unique, tankless system for delivering inhaled nitric oxide to patients in critical care settings. Its innovative product is designed to be safer, more convenient, and more cost-effective than traditional methods, which could make it a game-changer in the respiratory care market.
At a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Atlanta, United States
- Employees
- 217
- Open positions
- 20
- Dealroom signal
- 72.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Intellectual Property, Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2023 | $30M | $500M | Petrichor | ↗ |
| SERIES EOther financing | Dec 2021 | $100M | $400M | MVM Life Science Partners | ↗ |
Growth signals
Latest recorded traffic for Vero Biotech is 7.2K monthly website visits, up 105.7% over the last three months. Vero Biotech's team grew 6.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Runway Growth Capital
MVM Life Science Partners- PEPetrichor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vero Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vero Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.